Table 3 Leukapheresis and manufacture details (n = 134 patients with attempted harvest).

From: Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme

 

Median/n

IQR/%

CD3 collected (x 109)

2.6

1.2–4.1

CD45 or TNC collected (x 109)

5.6

3.1–8.4

Satisfactory apheresis

134

100%

Apheresis days

1

1–1,

  

range 1–4

Satisfactory manufacture

128

95.5%

Manufacture failure

5*

3.7%

CAR T dose (106/kg) n = 112

2.8

2.0–3.5

CAR T dose (x 108) n = 13

1.5

1.4–1.6

CAR T-cell transduction efficiency %

17.4%

12–23.1%

Time from screening to infusion (days)

60

50–80

  1. *Details of manufacture failure patients and their outcomes can be found in Supplementary Table 3.
  2. TNC total nucleated cells.
Back to article page